APLA 2021 Registrations are Open
October 27, 2021
REGISTRATIONS FROM 10/21 TO 11/05
APLA, the Latin American Petrochemical and Chemical Association, is organizing the Virtual Annual Meeting 2021, on November 8th & 9th.
The event will be held in a 100% virtual environment in an ALL IN ONE platform: enabling participants to access live conferences and on demand too, access the list of attendees and generate business meeting opportunities.
The meeting presents a 2-day agenda that will feature a large conference program by recognized leaders and companies in the sector which will address thematic axes about sustainability in the industry, energy transition and the long-term vision of the industry leaders.
WHO IS AIMED AT:
- Presidents / VP / CEO.
- Directors and Managers.
- Technicians / Especialist.
- Leaders and area coordinators.
- Representatives.
Check the schedule and register for here.
INTERVIEWS MORE INTERVIEWS
"Ecuador has placed a lot of hope in this asset due to its size and its potential to unlock economic."
"Our exploration program for the next four years represents a comprehensive approach to hydrocarbon discovery across Angola's diverse geological provinces."
"By targeting committed investors and maintaining strong regulatory and Indigenous relations, the province hopes to accelerate responsible mineral development and establish itself as a serious, results-oriented jurisdiction."
"There is still a lot of work in Cabinda, especially with ageing fields that require ongoing maintenance and the potential for new developments."
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
MORE PREVIOUSLY PUBLISHED
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
MORE PREVIOUSLY PUBLISHED
MACIG
SUBSCRIBE TO OUR NEWSLETTER
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
